Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

HCA Healthcare (HCA)

NYSE: HCA · Medical Facilities · Nashville, TN

Our rating: Positive

Positive reaffirmed at $473.19, moderate conviction, October 30, 2026.

Breaks if: The Positive call rests on continued cash generation and revenue momentum. It would be wrong if free-cash-flow margin — free cash flow divided by revenue — falls below 8% for two consecutive quarterly reports (the current figure is approximately 10.2%) or if year-over-year revenue growth decelerates to below 3% in two straight prints, either of which would indicate the operating durability assumed here has broken down. A 20% drawdown from the current price within twelve months, absent a broad market move of comparable size, would also signal that the market is pricing in a deterioration this desk has not yet seen in the filings.

Key figures

Market value$99.3B
Revenue, last 12 months$78.7B
Net income, last 12 months$6.8B
Free cash flow, last 12 months$6.0B
Price to earnings14.7×
Free cash flow yield6.0%
Dividend yield0.6%
Operating marginn/a
Return on equityn/a
Beta to the S&P 5000.26
Volatility, annualized29.6%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$19.8B3.6%$7.27$3.1B
June 30, 2026$20.2B8.7%$7.62$1.1B
March 31, 2026$19.1B4.3%$7.15$895M
December 31, 2025$19.5B6.7%$8.10$870M
September 30, 2025$19.2B9.6%$6.96$3.1B
June 30, 2025$18.6B6.4%$6.83$3.0B
March 31, 2025$18.3B5.7%$6.45$660M
December 31, 2024$18.3B5.7%$5.63$1.3B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

18 ledger entries and 51 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.